BiaPulse™ Device
Onychomycosis (Toenail Fungus)
Pre-clinicalActive
Key Facts
About BiaCure Therapies
BiaCure Therapies is targeting the significant unmet need in onychomycosis treatment with its proprietary BiaPulse™ device. The technology aims to overcome the limitations of current topical and oral therapies—low efficacy and safety concerns—by delivering precise energy to the nail bed. Led by a seasoned CEO with a track record of successful medical device exits, the company is developing a system that includes a reusable energy source and custom, AI-generated 3D applicators tailored to individual patient anatomy. The device is currently under development and not yet available for sale.
View full company profileTherapeutic Areas
Other Onychomycosis (Toenail Fungus) Drugs
| Drug | Company | Phase |
|---|---|---|
| MOB-015 | Moberg Pharma | Marketed |